Literature DB >> 29188497

Bexarotene, a Selective RXRα Agonist, Reverses Hypotension Associated with Inflammation and Tissue Injury in a Rat Model of Septic Shock.

Bahar Tunctan1, Sefika P Kucukkavruk2, Meryem Temiz-Resitoglu2, Demet S Guden2, Ayse N Sari2, Seyhan Sahan-Firat2.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that can activate or inhibit the expression of many target genes by forming a heterodimer complex with the retinoid X receptor (RXR). The aim of this study was to investigate effects of bexarotene, a selective RXRα agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARα/β/γ-RXRα heterodimer formation in a rat model of septic shock. Rats were injected with dimethyl sulfoxide or bexarotene 1 h after administration of saline or lipopolysaccharide (LPS). Mean arterial pressure (MAP) and heart rate (HR) were recorded from rats, which had received either saline or LPS before and after 1, 2, 3, and 4 h. Serum iNOS, LTB4, myeloperoxidase (MPO), and lactate dehydrogenase (LDH) levels as well as tissue iNOS and CYP4F6 mRNA expression in addition to PPARα/β/γ and RXRα proteins were measured. LPS-induced decrease in MAP and increase in HR were associated with a decrease in PPARα/β/γ-RXRα heterodimer formation and CYP4F6 mRNA expression. LPS also caused an increase in systemic iNOS, LTB4, MPO, and LDH levels as well as iNOS mRNA expression. Bexarotene at 0.1 mg/kg (i.p.) prevented the LPS-induced changes, except tachycardia. The results suggest that increased formation of PPARα/β/γ-RXRα heterodimers and CYP4F6 expression/activity in addition to decreased iNOS expression contributes to the beneficial effect of bexarotene to prevent the hypotension associated with inflammation and tissue injury during rat endotoxemia.

Entities:  

Keywords:  CYP4F6; PPARα/β/γ-RXRα; bexarotene; iNOS; inflammation; lipopolysaccharide

Mesh:

Substances:

Year:  2018        PMID: 29188497     DOI: 10.1007/s10753-017-0691-5

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  47 in total

Review 1.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

Review 2.  Preclinical sepsis models.

Authors:  Tom van der Poll
Journal:  Surg Infect (Larchmt)       Date:  2012-10-09       Impact factor: 2.150

Review 3.  Natural and Structure-based RXR Ligand Scaffolds and Their Functions.

Authors:  Marta Dominguez; Susana Alvarez; Angel R de Lera
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

Review 4.  Regulation of the nongenomic actions of retinoid X receptor-α by targeting the coregulator-binding sites.

Authors:  Xiao-kun Zhang; Ying Su; Liqun Chen; Fan Chen; Jie Liu; Hu Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-12-01       Impact factor: 6.150

Review 5.  A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid.

Authors:  Bahar Tunctan; Belma Korkmaz; Ayse Nihal Sari; Meltem Kacan; Demet Unsal; Mehmet Sami Serin; C Kemal Buharalioglu; Seyhan Sahan-Firat; Wolf-Hagen Schunck; John R Falck; Kafait U Malik
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2012

6.  Piroxicam reverses endotoxin-induced hypotension in rats: contribution of vasoactive eicosanoids and nitric oxide.

Authors:  C Kemal Buharalioglu; Belma Korkmaz; Tuba Cuez; Seyhan Sahan-Firat; Ayse Nihal Sari; Kafait U Malik; Bahar Tunctan
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-05-06       Impact factor: 4.080

Review 7.  Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?

Authors:  Alex Dyson; Mervyn Singer
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

8.  CYP4Fs expression in rat brain correlates with changes in LTB4 levels after traumatic brain injury.

Authors:  Ying Wang; Jing Zhao; Auinash Kalsotra; Cheri M Turman; Raymond J Grill; Pramod K Dash; Henry W Strobel
Journal:  J Neurotrauma       Date:  2008-10       Impact factor: 5.269

9.  Effects of 5,14-HEDGE, a 20-HETE mimetic, on lipopolysaccharide-induced changes in MyD88/TAK1/IKKβ/IκB-α/NF-κB pathway and circulating miR-150, miR-223, and miR-297 levels in a rat model of septic shock.

Authors:  A Nihal Sari; Belma Korkmaz; Mehmet Sami Serin; Meltem Kacan; Demet Unsal; C Kemal Buharalioglu; Seyhan Sahan Firat; Vijay L Manthati; John R Falck; Kafait U Malik; Bahar Tunctan
Journal:  Inflamm Res       Date:  2014-06-12       Impact factor: 4.575

Review 10.  Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.

Authors:  Bogna Grygiel-Górniak
Journal:  Nutr J       Date:  2014-02-14       Impact factor: 3.271

View more
  9 in total

1.  Suppression of TLR4/MyD88/TAK1/NF-κB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.

Authors:  Sefika Pinar Senol; Meryem Temiz-Resitoglu; Demet Sinem Guden; Ayse Nihal Sari; Seyhan Sahan-Firat; Bahar Tunctan
Journal:  Neurochem Res       Date:  2021-01-02       Impact factor: 3.996

2.  Ex Vivo Investigation of Bexarotene and Nicotinamide Function as a Protectıve Agent on Rat Synaptosomes Treated with Aβ(1-42).

Authors:  Ceyhan Hacioglu; Fatih Kar; Gungor Kanbak
Journal:  Neurochem Res       Date:  2021-01-11       Impact factor: 3.996

3.  Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.

Authors:  Hailin Liu; Shengwei Liu; Xiaocui Tian; Qian Wang; Jiangyan Rao; Yucun Wang; Fei Xiang; Hang Zheng; Lu Xu; Zhi Dong
Journal:  Neurochem Res       Date:  2019-11-03       Impact factor: 3.996

4.  Dexmedetomidine Enhances Autophagy via α2-AR/AMPK/mTOR Pathway to Inhibit the Activation of NLRP3 Inflammasome and Subsequently Alleviates Lipopolysaccharide-Induced Acute Kidney Injury.

Authors:  Tianyuan Yang; Xiujing Feng; Yuan Zhao; Haiyang Zhang; Hailin Cui; Mian Wei; Haotian Yang; Honggang Fan
Journal:  Front Pharmacol       Date:  2020-06-24       Impact factor: 5.810

5.  Mediatory roles of leukotriene B4 receptors in LPS-induced endotoxic shock.

Authors:  Sun-Young Kwon; MyungJa Ro; Jae-Hong Kim
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

6.  Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling.

Authors:  Xiaohong Ye; Hua Wu; Luoyan Sheng; Yi-Xin Liu; Fang Ye; Mo Wang; Hu Zhou; Ying Su; Xiao-Kun Zhang
Journal:  Nat Commun       Date:  2019-04-01       Impact factor: 14.919

7.  Bexarotene Exerts Protective Effects Through Modulation of the Cerebral Vascular Smooth Muscle Cell Phenotypic Transformation by Regulating PPARγ/FLAP/LTB4 After Subarachnoid Hemorrhage in Rats.

Authors:  Zhaosi Zhang; Guosheng Zhao; Liu Liu; Junchi He; Rami Darwazeh; Han Liu; Hong Chen; Chao Zhou; Zongduo Guo; Xiaochuan Sun
Journal:  Cell Transplant       Date:  2019-04-22       Impact factor: 4.064

8.  Synthesis and biological evaluation of (3/4-(pyrimidin-2-ylamino)benzoyl)-based hydrazine-1-carboxamide/carbothioamide derivatives as novel RXRα antagonists.

Authors:  Jingbo Qin; Jie Liu; Chunxiao Wu; Jianwen Xu; Bowen Tang; Kaiqiang Guo; Xiaohui Chen; Weihao Liu; Tong Wu; Hu Zhou; Meijuan Fang; Zhen Wu
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 9.  The Regulatory Roles of PPARs in Skeletal Muscle Fuel Metabolism and Inflammation: Impact of PPAR Agonism on Muscle in Chronic Disease, Contraction and Sepsis.

Authors:  Hannah Crossland; Dumitru Constantin-Teodosiu; Paul L Greenhaff
Journal:  Int J Mol Sci       Date:  2021-09-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.